Heska introduces ultranasal FVRCP vaccine
FORT COLLINS, COLO.-Heska introduces the FVRCP vaccine providing protection against the most prevalent causes of feline upper respiratory disease and feline panleukopenia without needles.
FORT COLLINS, COLO.—Heska introduces the FVRCP vaccine providing protection against the most prevalent causes of feline upper respiratory disease and feline panleukopenia without needles.
The Feline UltraNasal⢠FVRCP Vaccine protects against rhinotracheitis virus, calicivirus and panleukopenia. The Feline UltraNasal⢠FVRC Vaccine protects against rhinotracheitis virus and calicivirus. The vaccines are packaged in easily administered 0.2 mL doses and are administered intranasally.
The new, milder formulation delivers effective protection mucosally, without risk of injection site sarcomas and related reactions. Additionally, mucosal administration results in more rapid protection against rhinotracheitis virus—within four days.
The Feline UltraNasal⢠FVRCP and FVRC Vaccines provide effective, safe alternatives to needles, the company says.
For fastest response, call
(800) 464-3752
